• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.

作者信息

Hanna Paul, Strohbehn Ian, Moreno Daiana, Harden Destiny, Seethapathy Harish, Gupta Shruti, Lee Meghan, Ouyang Tianqi, Frigault Matthew, Sise Meghan E

机构信息

Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.

Department of Medicine, Division of Nephrology, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Bone Marrow Transplant. 2022 Oct;57(10):1623-1625. doi: 10.1038/s41409-022-01767-7. Epub 2022 Aug 3.

DOI:10.1038/s41409-022-01767-7
PMID:35922564
Abstract
摘要

相似文献

1
Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.嵌合抗原受体T细胞疗法与自体造血干细胞移植治疗弥漫性大B细胞淋巴瘤后短期和长期肾脏不良结局的比较。
Bone Marrow Transplant. 2022 Oct;57(10):1623-1625. doi: 10.1038/s41409-022-01767-7. Epub 2022 Aug 3.
2
Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.从德国医疗保健支付方的角度分析复发或难治性弥漫性大B细胞淋巴瘤患者接受异基因干细胞移植或嵌合抗原受体T细胞疗法的成本
Bone Marrow Transplant. 2024 Apr;59(4):572-574. doi: 10.1038/s41409-024-02228-z. Epub 2024 Feb 6.
3
Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population.不适合移植但适合嵌合抗原受体 T 细胞：一个真实而相关的人群。
Eur J Cancer. 2022 Nov;175:246-253. doi: 10.1016/j.ejca.2022.08.019. Epub 2022 Sep 24.
4
Successful Continuation of Clozapine in Conjunction With Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy: Case Report.氯氮平与嵌合抗原受体T细胞（CAR-T）免疫疗法联合使用的成功延续：病例报告
Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e194-e197. doi: 10.1016/j.clml.2020.10.010. Epub 2020 Oct 22.
5
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.自体移植后继发性中枢神经系统淋巴瘤的嵌合抗原受体 T 细胞治疗：一例报告。
Medicine (Baltimore). 2021 Nov 5;100(44):e27733. doi: 10.1097/MD.0000000000027733.
6
Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.异基因干细胞移植后嵌合抗原受体T细胞疗法治疗复发/难治性大B细胞淋巴瘤
Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10.
7
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.新旧免疫疗法：造血干细胞移植、嵌合抗原受体 T 细胞和双特异性抗体治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.
8
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.造血干细胞移植和嵌合抗原受体 T 细胞治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Immunotherapy. 2020 Sep;12(13):997-1006. doi: 10.2217/imt-2020-0075. Epub 2020 Aug 5.
9
CAR-T in B-Cell Lymphomas: The Past, Present, and Future.嵌合抗原受体 T 细胞疗法在 B 细胞淋巴瘤中的过去、现在与未来。
Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):e261-e268. doi: 10.1016/j.clml.2021.10.003. Epub 2021 Oct 15.
10
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.嵌合抗原受体T细胞疗法治疗不同大B细胞淋巴瘤亚型后的疗效。
Haematologica. 2024 Aug 1;109(8):2716-2720. doi: 10.3324/haematol.2024.285010.

引用本文的文献

1
Novel Biomarkers and Imaging Tests for Acute Kidney Injury Diagnosis in Patients with Cancer.用于癌症患者急性肾损伤诊断的新型生物标志物和影像学检查
Kidney360. 2025 Jan 1;6(1):167-174. doi: 10.34067/KID.0000000660. Epub 2024 Nov 21.
2
Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes.CAR-T 细胞治疗血液系统疾病患者的急性肾损伤：危险因素、临床表现及对结局的影响。
Sci Rep. 2024 Nov 6;14(1):26886. doi: 10.1038/s41598-024-77720-z.
3
Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.

本文引用的文献

1
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.嵌合抗原受体 T 细胞治疗后急性肾损伤：发生率低且恢复迅速。
Biol Blood Marrow Transplant. 2020 Jun;26(6):1071-1076. doi: 10.1016/j.bbmt.2020.02.012. Epub 2020 Feb 20.
2
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.嵌合抗原受体 T 细胞（CAR-T）治疗弥漫性大 B 细胞淋巴瘤后急性肾损伤和电解质异常。
Am J Kidney Dis. 2020 Jul;76(1):63-71. doi: 10.1053/j.ajkd.2019.10.011. Epub 2020 Jan 20.
3
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
血液系统恶性肿瘤患者接受嵌合抗原受体T细胞治疗后的短暂性急性肾损伤。
Clin Kidney J. 2024 Feb 20;17(3):sfae027. doi: 10.1093/ckj/sfae027. eCollection 2024 Mar.
4
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.细胞治疗相关毒性的管理和预防：早期和晚期并发症。
Curr Oncol. 2023 May 15;30(5):5003-5023. doi: 10.3390/curroncol30050378.
难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
4
Renal Complications of Hematopoietic-Cell Transplantation.造血细胞移植的肾脏并发症
N Engl J Med. 2016 Jun 9;374(23):2256-67. doi: 10.1056/NEJMra1404711.
5
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
6
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.